Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Review of Pharmacoeconomics & Outcomes Research|May 1, 2009
Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experienceRachel Grocott
International Journal of Environmental Research and Public Health|July 10, 2010
Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness thresholdScott Metcalfe, Rachel Grocott
The New Zealand Medical Journal|October 15, 2005
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritisRachel Grocott, Scott Metcalfe
The New Zealand Medical Journal|September 19, 2013
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysisRachel Grocott, Scott Metcalfe, Paul Alexander, et al.
The New Zealand Medical Journal|December 7, 2011
Do pharmaceutical score cards give us the answers we seek?Peter Moodie, Scott Metcalfe, Matthew Poynton
The New Zealand Medical Journal|December 3, 2014
Self-monitoring blood glucose test strip use with diabetes medicines in people with types 1 and 2 diabetes in New ZealandScott Metcalfe, Peter Moodie, Hew Norris, et al.
BMJ Open|January 29, 2025
Widening access to isotretinoin in primary care: an evaluation of New Zealand national dispensing data for isotretinoin for acne, 2008-2023Peter Moodie, Rachel Petronella Roskvist, Jason Arnold, et al.
The New Zealand Medical Journal|September 29, 2011
Terminations of pregnancy associated with isotretinoin use in New ZealandPeter Moodie, Richard Jaine, Jason Arnold, et al.
The New Zealand Medical Journal|December 7, 2011
Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicityPeter Moodie, Richard Jaine, Jason Arnold, et al.
Pageof 1